Latest Insider Transactions at Chemo Centryx, Inc. (CCXI)
This section provides a real-time view of insider transactions for Chemo Centryx, Inc. (CCXI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ChemoCentryx, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ChemoCentryx, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 20
2022
|
Thomas J. Schall President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,393,352
-100.0%
|
-
|
|
Oct 20
2022
|
Joseph M Feczko Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
148,127
-100.0%
|
-
|
|
Oct 20
2022
|
James L Tyree Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,138
-100.0%
|
-
|
|
Oct 20
2022
|
Susan M Kanaya Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
132,717
-100.0%
|
-
|
|
Oct 20
2022
|
Susan M Kanaya Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
91,317
-100.0%
|
-
|
|
Oct 20
2022
|
Geoffrey M. Parker Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
26,076
-100.0%
|
-
|
|
Oct 20
2022
|
Geoffrey M. Parker Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
107,997
-100.0%
|
-
|
|
Oct 20
2022
|
Thomas A. Edwards Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
143,306
-100.0%
|
-
|
|
Oct 20
2022
|
Jennifer Lyn Herron Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,237
-100.0%
|
-
|
|
Oct 20
2022
|
Rita Jain EVP, Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
35,863
-100.0%
|
-
|
|
Oct 20
2022
|
Tausif Butt EVP, Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,870
-100.0%
|
-
|
|
Oct 20
2022
|
Markus J. Cappel Chief Bus. Officer & Treasurer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
87,658
-100.0%
|
-
|
|
Aug 16
2022
|
Susan M Kanaya Director |
SELL
Open market or private sale
|
Direct |
19,898
-17.89%
|
$994,900
$50.95 P/Share
|
|
Aug 16
2022
|
Susan M Kanaya Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,898
+15.18%
|
$198,980
$10.86 P/Share
|
|
Aug 04
2022
|
Thomas J. Schall President and CEO |
SELL
Open market or private sale
|
Direct |
130,000
-5.15%
|
$6,500,000
$50.24 P/Share
|
|
Aug 04
2022
|
Thomas J. Schall President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+4.9%
|
$1,820,000
$14.28 P/Share
|
|
Aug 04
2022
|
Susan M Kanaya Director |
SELL
Open market or private sale
|
Direct |
46,298
-33.64%
|
$2,314,900
$50.17 P/Share
|
|
Aug 04
2022
|
Susan M Kanaya Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,298
+15.42%
|
$277,788
$6.43 P/Share
|
|
Aug 04
2022
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
10,000
-52.25%
|
$500,000
$50.22 P/Share
|
|
Aug 04
2022
|
Markus J. Cappel Chief Bus. Officer & Treasurer |
SELL
Open market or private sale
|
Direct |
7,564
-7.94%
|
$378,200
$50.22 P/Share
|
|
Jun 28
2022
|
Jennifer Lyn Herron Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,237
+50.0%
|
-
|
|
Jun 09
2022
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
3,863
-8.42%
|
$96,575
$25.93 P/Share
|
|
May 26
2022
|
Thomas A. Edwards Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,723
+9.89%
|
-
|
|
May 20
2022
|
Rita Jain EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,726
+17.72%
|
-
|
|
May 20
2022
|
Henry A Mckinnell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,726
+9.6%
|
-
|
|
May 20
2022
|
Geoffrey M. Parker Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
7,726
+26.82%
|
-
|
|
May 20
2022
|
James L Tyree Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,726
+25.14%
|
-
|
|
May 02
2022
|
Geoffrey M. Parker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+9.13%
|
$175,000
$14.42 P/Share
|
|
Mar 27
2022
|
Rita Jain EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,251
+15.73%
|
-
|
|
Jan 21
2022
|
Joseph M Feczko Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+11.67%
|
$562,500
$15.16 P/Share
|
|
Jan 01
2022
|
Markus J. Cappel Chief Bus. Officer & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,538
-10.81%
|
$415,368
$36.41 P/Share
|
|
Jan 01
2022
|
Markus J. Cappel Chief Bus. Officer & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,934
+6.55%
|
-
|
|
Jan 01
2022
|
Susan M Kanaya Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
16,847
-11.26%
|
$606,492
$36.41 P/Share
|
|
Jan 01
2022
|
Susan M Kanaya Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
30,799
+6.89%
|
-
|
|
Jan 01
2022
|
Thomas J. Schall President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
45,698
-1.87%
|
$1,645,128
$36.41 P/Share
|
|
Jan 01
2022
|
Thomas J. Schall President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
84,234
+1.15%
|
-
|
|
Dec 17
2021
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
37,500
-30.93%
|
$1,275,000
$34.59 P/Share
|
|
Dec 17
2021
|
James L Tyree Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+28.72%
|
$487,500
$13.52 P/Share
|
|
Dec 01
2021
|
Thomas J. Schall President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,936
+0.96%
|
$551,232
$12.29 P/Share
|
|
Oct 12
2021
|
Vifor (International) LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,000,000
-43.51%
|
$156,000,000
$39.43 P/Share
|
|
May 21
2021
|
Rita Jain EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+16.92%
|
-
|
|
May 21
2021
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
2,454
-13.84%
|
$22,086
$9.76 P/Share
|
|
May 21
2021
|
James L Tyree Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+20.81%
|
-
|
|
May 21
2021
|
Geoffrey M. Parker Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,660
+25.87%
|
-
|
|
May 20
2021
|
Thomas A. Edwards Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,726
+5.71%
|
-
|
|
May 20
2021
|
Joseph M Feczko Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,726
+6.53%
|
-
|
|
May 07
2021
|
Tausif Butt EVP, Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,870
+50.0%
|
$119,570
$11.06 P/Share
|
|
Mar 27
2021
|
Rita Jain EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,251
+22.37%
|
-
|
|
Mar 10
2021
|
Geoffrey M. Parker Director |
SELL
Bona fide gift
|
Indirect |
4,000
-31.52%
|
-
|
|
Mar 05
2021
|
Geoffrey M. Parker Director |
SELL
Open market or private sale
|
Indirect |
30,000
-45.14%
|
$1,680,000
$56.33 P/Share
|